OBJECTIVE: To evaluate the long term (4 years) efficacy of deep brain stimulation (DBS) of the subthalamic nucleus (STN) in advanced Parkinson's disease. METHODS: We performed a double blind crossover evaluation of the efficacy of DBS of the STN in the "off" medication condition in 10 patients with Parkinson's disease. Assessments included the Unified Parkinson's Disease Rating Scale (UPDRS) part III (motor) and two timed tests (arm tapping and walking). Open evaluation of the effect of stimulation in the off and on drug states preoperatively and at 1 and 4 years postoperatively was also conducted. The latter assessment included the UPDRS parts II (activities of daily living) and III (dyskinesia scale and global assessment) as judged by the patient and examiner. The mean amount of levodopa daily dose at base line, 1 year, and 4 years after surgery was compared. RESULTS: A significant (p<0.04) effect of stimulation was observed in the overall group regarding both the UPDRS motor and the timed tests. Open evaluation also showed a significant benefit of STN DBS with respect to preoperative assessment in both the motor and activities of daily living scales, dyskinesia scale, and in global assessment. Levodopa daily dose was reduced by 48% and 50% at 1 and 4 years, respectively. There was no difference between the 1 and 4 years evaluations in any of the parameters evaluated. Complications due to stimulation were minor. CONCLUSIONS:DBS of the STN provides a significant and persistent anti-parkinsonian effect in advanced Parkinson's disease 4 years after surgery.
RCT Entities:
OBJECTIVE: To evaluate the long term (4 years) efficacy of deep brain stimulation (DBS) of the subthalamic nucleus (STN) in advanced Parkinson's disease. METHODS: We performed a double blind crossover evaluation of the efficacy of DBS of the STN in the "off" medication condition in 10 patients with Parkinson's disease. Assessments included the Unified Parkinson's Disease Rating Scale (UPDRS) part III (motor) and two timed tests (arm tapping and walking). Open evaluation of the effect of stimulation in the off and on drug states preoperatively and at 1 and 4 years postoperatively was also conducted. The latter assessment included the UPDRS parts II (activities of daily living) and III (dyskinesia scale and global assessment) as judged by the patient and examiner. The mean amount of levodopa daily dose at base line, 1 year, and 4 years after surgery was compared. RESULTS: A significant (p<0.04) effect of stimulation was observed in the overall group regarding both the UPDRS motor and the timed tests. Open evaluation also showed a significant benefit of STN DBS with respect to preoperative assessment in both the motor and activities of daily living scales, dyskinesia scale, and in global assessment. Levodopa daily dose was reduced by 48% and 50% at 1 and 4 years, respectively. There was no difference between the 1 and 4 years evaluations in any of the parameters evaluated. Complications due to stimulation were minor. CONCLUSIONS: DBS of the STN provides a significant and persistent anti-parkinsonian effect in advanced Parkinson's disease 4 years after surgery.
Authors: J Volkmann; V Sturm; P Weiss; J Kappler; J Voges; A Koulousakis; R Lehrke; H Hefter; H J Freund Journal: Ann Neurol Date: 1998-12 Impact factor: 10.422
Authors: J L Houeto; V Mesnage; L Mallet; B Pillon; M Gargiulo; S Tezenas du Moncel; A M Bonnet; B Pidoux; D Dormont; P Cornu; Y Agid Journal: J Neurol Neurosurg Psychiatry Date: 2002-06 Impact factor: 10.154
Authors: F Godinho; S Thobois; M Magnin; M Guenot; G Polo; I Benatru; J Xie; A Salvetti; L Garcia-Larrea; E Broussolle; P Mertens Journal: J Neurol Date: 2006-06-20 Impact factor: 4.849
Authors: Courtney R Schadt; Katie L Cox; Michael G Tramontana; Daniel W Byrne; Thomas L Davis; John Y Fang; Peter E Konrad; Bhavna Padaliya; Robert W Mutter; Chandler E Gill; Caralee R Richardson; P David Charles Journal: J Natl Med Assoc Date: 2006-07 Impact factor: 1.798
Authors: V Fraix; J-L Houeto; C Lagrange; C Le Pen; P Krystkowiak; D Guehl; C Ardouin; M-L Welter; F Maurel; L Defebvre; A Rougier; A-L Benabid; V Mesnage; M Ligier; S Blond; P Burbaud; B Bioulac; A Destée; P Cornu; P Pollak Journal: J Neurol Neurosurg Psychiatry Date: 2006-04 Impact factor: 10.154
Authors: D De Gaspari; C Siri; A Landi; R Cilia; A Bonetti; F Natuzzi; L Morgante; C B Mariani; E Sganzerla; G Pezzoli; A Antonini Journal: J Neurol Neurosurg Psychiatry Date: 2006-04 Impact factor: 10.154
Authors: Claudio Da Cunha; Suelen L Boschen; Alexander Gómez-A; Erika K Ross; William S J Gibson; Hoon-Ki Min; Kendall H Lee; Charles D Blaha Journal: Neurosci Biobehav Rev Date: 2015-02-12 Impact factor: 8.989